Buy the Dip in CRDF: Onvansertib’s First-Line mCRC Data Deserves a Re‑rating
Cardiff Oncology’s shares look oversold after the market largely ignored a 64% objective response rate in first-line RAS-mutated mCRC. With a sub-$110M market cap, recent presentations and a tight float loaded with short interest, this is an actionable event-driven long with defined risk control.